Cargando…
Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
BACKGROUND: To evaluate the association between immune-related adverse events (irAEs) and the clinical outcomes and also between irAEs and the post-treatment changes in the relative eosinophil count (REC) in advanced urothelial carcinoma (UC) patients treated with pembrolizumab. MATERIALS AND METHOD...
Autores principales: | Furubayashi, Nobuki, Minato, Akinori, Negishi, Takahito, Sakamoto, Naotaka, Song, Yoohyun, Hori, Yoshifumi, Tomoda, Toshihisa, Harada, Mirii, Tamura, Shingo, Miura, Akihiro, Komori, Hiroki, Kuroiwa, Kentaro, Seki, Narihito, Fujimoto, Naohiro, Nakamura, Motonobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078345/ https://www.ncbi.nlm.nih.gov/pubmed/35535266 http://dx.doi.org/10.2147/CMAR.S360473 |
Ejemplares similares
-
The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2021) -
The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status
por: Furubayashi, Nobuki, et al.
Publicado: (2022) -
Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy
por: Furubayashi, Nobuki, et al.
Publicado: (2021) -
Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021) -
Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
por: Furubayashi, Nobuki, et al.
Publicado: (2020)